table of content
1 Study Coverage
1.1 Myasthenia Gravis Drugs Product Introduction
1.2 Global Myasthenia Gravis Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Myasthenia Gravis Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Myasthenia Gravis Drugs Sales in Volume for the Year 2017-2028
1.3 United States Myasthenia Gravis Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Myasthenia Gravis Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Myasthenia Gravis Drugs Sales in Volume for the Year 2017-2028
1.4 Myasthenia Gravis Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Myasthenia Gravis Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Myasthenia Gravis Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Myasthenia Gravis Drugs Market Dynamics
1.5.1 Myasthenia Gravis Drugs Industry Trends
1.5.2 Myasthenia Gravis Drugs Market Drivers
1.5.3 Myasthenia Gravis Drugs Market Challenges
1.5.4 Myasthenia Gravis Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Myasthenia Gravis Drugs Market Segment by Type
2.1.1 Anticholinesterases
2.1.2 Immunosuppressants
2.1.3 Intravenous Immune Globulins
2.2 Global Myasthenia Gravis Drugs Market Size by Type
2.2.1 Global Myasthenia Gravis Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Myasthenia Gravis Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Myasthenia Gravis Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Myasthenia Gravis Drugs Market Size by Type
2.3.1 United States Myasthenia Gravis Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Myasthenia Gravis Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Myasthenia Gravis Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Myasthenia Gravis Drugs Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.2 Global Myasthenia Gravis Drugs Market Size by Application
3.2.1 Global Myasthenia Gravis Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Myasthenia Gravis Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Myasthenia Gravis Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Myasthenia Gravis Drugs Market Size by Application
3.3.1 United States Myasthenia Gravis Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Myasthenia Gravis Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Myasthenia Gravis Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Myasthenia Gravis Drugs Competitor Landscape by Company
4.1 Global Myasthenia Gravis Drugs Market Size by Company
4.1.1 Top Global Myasthenia Gravis Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Myasthenia Gravis Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Myasthenia Gravis Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Myasthenia Gravis Drugs Price by Manufacturer (2017-2022)
4.2 Global Myasthenia Gravis Drugs Concentration Ratio (CR)
4.2.1 Myasthenia Gravis Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Myasthenia Gravis Drugs in 2021
4.2.3 Global Myasthenia Gravis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Myasthenia Gravis Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Myasthenia Gravis Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Myasthenia Gravis Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Myasthenia Gravis Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Myasthenia Gravis Drugs Market Size by Company
4.5.1 Top Myasthenia Gravis Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Myasthenia Gravis Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Myasthenia Gravis Drugs Sales by Players (2020, 2021 & 2022)
5 Global Myasthenia Gravis Drugs Market Size by Region
5.1 Global Myasthenia Gravis Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Myasthenia Gravis Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Myasthenia Gravis Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Myasthenia Gravis Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Myasthenia Gravis Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Myasthenia Gravis Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Myasthenia Gravis Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Myasthenia Gravis Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Myasthenia Gravis Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Myasthenia Gravis Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Myasthenia Gravis Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Myasthenia Gravis Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Myasthenia Gravis Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Myasthenia Gravis Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Myasthenia Gravis Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Myasthenia Gravis Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Myasthenia Gravis Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Flamel Technologies
7.1.1 Flamel Technologies Corporation Information
7.1.2 Flamel Technologies Description and Business Overview
7.1.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Flamel Technologies Myasthenia Gravis Drugs Products Offered
7.1.5 Flamel Technologies Recent Development
7.2 F. Hoffmann-La Roche
7.2.1 F. Hoffmann-La Roche Corporation Information
7.2.2 F. Hoffmann-La Roche Description and Business Overview
7.2.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Products Offered
7.2.5 F. Hoffmann-La Roche Recent Development
7.3 Grifols
7.3.1 Grifols Corporation Information
7.3.2 Grifols Description and Business Overview
7.3.3 Grifols Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Grifols Myasthenia Gravis Drugs Products Offered
7.3.5 Grifols Recent Development
7.4 Pfizer
7.4.1 Pfizer Corporation Information
7.4.2 Pfizer Description and Business Overview
7.4.3 Pfizer Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Pfizer Myasthenia Gravis Drugs Products Offered
7.4.5 Pfizer Recent Development
7.5 Takeda
7.5.1 Takeda Corporation Information
7.5.2 Takeda Description and Business Overview
7.5.3 Takeda Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Takeda Myasthenia Gravis Drugs Products Offered
7.5.5 Takeda Recent Development
7.6 Novartis
7.6.1 Novartis Corporation Information
7.6.2 Novartis Description and Business Overview
7.6.3 Novartis Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Novartis Myasthenia Gravis Drugs Products Offered
7.6.5 Novartis Recent Development
7.7 Bausch Health
7.7.1 Bausch Health Corporation Information
7.7.2 Bausch Health Description and Business Overview
7.7.3 Bausch Health Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Bausch Health Myasthenia Gravis Drugs Products Offered
7.7.5 Bausch Health Recent Development
7.8 Alexion Pharmaceuticals
7.8.1 Alexion Pharmaceuticals Corporation Information
7.8.2 Alexion Pharmaceuticals Description and Business Overview
7.8.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Products Offered
7.8.5 Alexion Pharmaceuticals Recent Development
7.9 Catalyst Pharmaceuticals
7.9.1 Catalyst Pharmaceuticals Corporation Information
7.9.2 Catalyst Pharmaceuticals Description and Business Overview
7.9.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Products Offered
7.9.5 Catalyst Pharmaceuticals Recent Development
7.10 CSL
7.10.1 CSL Corporation Information
7.10.2 CSL Description and Business Overview
7.10.3 CSL Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 CSL Myasthenia Gravis Drugs Products Offered
7.10.5 CSL Recent Development
7.11 Curavac
7.11.1 Curavac Corporation Information
7.11.2 Curavac Description and Business Overview
7.11.3 Curavac Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Curavac Myasthenia Gravis Drugs Products Offered
7.11.5 Curavac Recent Development
7.12 Cytokinetics
7.12.1 Cytokinetics Corporation Information
7.12.2 Cytokinetics Description and Business Overview
7.12.3 Cytokinetics Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Cytokinetics Products Offered
7.12.5 Cytokinetics Recent Development
7.13 Galencia
7.13.1 Galencia Corporation Information
7.13.2 Galencia Description and Business Overview
7.13.3 Galencia Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Galencia Products Offered
7.13.5 Galencia Recent Development
7.14 GlaxoSmithKline
7.14.1 GlaxoSmithKline Corporation Information
7.14.2 GlaxoSmithKline Description and Business Overview
7.14.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.14.4 GlaxoSmithKline Products Offered
7.14.5 GlaxoSmithKline Recent Development
7.15 Lupin Pharmaceuticals
7.15.1 Lupin Pharmaceuticals Corporation Information
7.15.2 Lupin Pharmaceuticals Description and Business Overview
7.15.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Lupin Pharmaceuticals Products Offered
7.15.5 Lupin Pharmaceuticals Recent Development
7.16 Mitsubishi Tanabe Pharma
7.16.1 Mitsubishi Tanabe Pharma Corporation Information
7.16.2 Mitsubishi Tanabe Pharma Description and Business Overview
7.16.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Mitsubishi Tanabe Pharma Products Offered
7.16.5 Mitsubishi Tanabe Pharma Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Myasthenia Gravis Drugs Industry Chain Analysis
8.2 Myasthenia Gravis Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Myasthenia Gravis Drugs Distributors
8.3 Myasthenia Gravis Drugs Production Mode & Process
8.4 Myasthenia Gravis Drugs Sales and Marketing
8.4.1 Myasthenia Gravis Drugs Sales Channels
8.4.2 Myasthenia Gravis Drugs Distributors
8.5 Myasthenia Gravis Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
